Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
XAB2
REST API REST API
Homo sapiens
XAB2 is differentially expressed in 152 experiments: 71 organism parts: bone marrow, cervix, ... (69 more);, 111 disease states: normal, acute promyelocytic leukemia, ... (109 more);, 44 cell types 160 cell lines 17 compound treatments and 63 other conditions.
Synonyms NTC90, HCRN, HCNP, SYF1
Orthologs Xab2 (Rattus norvegicus)   Xab2 (Mus musculus)   SYF1 (Saccharomyces cerevisiae)   XAB2 (Bos taurus)   xab2 (Danio rerio)   ENSCING00000006985 (Ciona intestinalis)   CG6197 (Drosophila melanogaster)   xab2 (Xenopus laevis)   XAB2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term RNA splicing, nucleotide-excision repair, protein binding, DNA repair, RNA processing, intracellular, transcription, DNA-dependent, nucleus, nuclear mRNA splicing, via spliceosome, binding, nucleoplasm, transcription-coupled nucleotide-excision repair, blastocyst development, catalytic step 2 spliceosome
InterPro Term TPR_repeat, TPR-contain, HAT
UniProt Accession Q9HCS7, Q68CN2, F5H315
Search EB-eye ENSG00000076924
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-803, E-MTAB-24, E-MTAB-25, ... (18 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (26 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
primary culture
2
E-GEOD-2450, E-GEOD-1657
ML2
1
E-MTAB-37
MCIXC
1
E-MTAB-37
Jurkat
1
E-MEXP-2197
SW48
1
E-MTAB-37
154 more value(s).


Cell type

studied in E-GEOD-18811, E-GEOD-22529, E-AFMX-5, E-GEOD-19069, E-MTAB-25, ... (22 experiments)

Factor Value U/D Experiments
adipocyte
2
E-MTAB-25, E-AFMX-5
epithelial cell
2
E-GEOD-4483, E-MEXP-2034
immortalised T lymphocytes
1
E-GEOD-13909
germ cell
1
E-MTAB-25
CD34+ hematopoietic progenitor cell
1
E-GEOD-19240
purified B cells from peripheral blood from donors 60 years of age and older
1
E-GEOD-22529
38 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-22529, E-MEXP-1121, E-GEOD-22148, E-GEOD-9692, ... (30 experiments)

Factor Value U/D Experiments
dermatomyositis
2
E-GEOD-1551, E-MTAB-62
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
carcinoma (undifferenciated)
1
E-MTAB-62
hepatocellular carcinoma, no satellite nodules
1
E-MTAB-62
Severe
1
E-GEOD-22148
myeloid leukemia
1
E-MTAB-37
105 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-GEOD-15205, E-GEOD-5824, E-MEXP-1335, ... (8 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-941, E-MEXP-1335
Cxcl12
1
E-GEOD-7307
bacterial endotoxin
1
1
E-GEOD-3284
unknown
1
E-GEOD-7307
estradiol
1
E-GEOD-20081
TNF
1
E-GEOD-15205
11 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
31
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21589, E-GEOD-16363, E-GEOD-18995 ... (5 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-1751

double amplification
studied in E-GEOD-22601

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-17385, E-GEOD-20847

Genotype
studied in E-GEOD-18005, E-GEOD-17347

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-7011, E-MEXP-2657

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-MEXP-2069, E-TABM-666, ... (24 experiments)

Infection
studied in E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-GEOD-1657

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

RNAi
studied in E-MEXP-1509, E-MEXP-101

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Processing time: 0.517 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM